Equities Analysts Set Expectations for CRBU Q3 Earnings

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS estimate for Caribou Biosciences to a loss of $0.26 from a previously projected loss of $0.48. Analysts expect the company to remain unprofitable in subsequent years.
• Caribou reported a quarterly loss of $0.24 per share, beating the $0.32 consensus estimate, but revenue of $1.50 million fell short of the $2.28 million forecast.
• Analyst sentiment is mixed but leans positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $7.75 versus a recent price of $1.57. Institutional investors own 77.51% of the company.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Brookline Capital Markets increased their Q3 2026 earnings estimates for shares of Caribou Biosciences in a report released on Thursday, August 13th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of ($0.26) for the quarter, up from their prior estimate of ($0.48). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.15) per share. Brookline Capital Markets also issued estimates for Caribou Biosciences' Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($1.35) EPS, FY2028 earnings at ($1.96) EPS, FY2029 earnings at ($3.52) EPS and FY2030 earnings at ($4.85) EPS.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Bank of America decreased their price target on Caribou Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a report on Friday. Finally, HC Wainwright increased their price objective on shares of Caribou Biosciences from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Caribou Biosciences presently has an average rating of "Moderate Buy" and an average target price of $7.75.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $1.57 on Tuesday. The business's 50-day moving average is $1.68 and its two-hundred day moving average is $1.84. The firm has a market capitalization of $155.71 million, a PE ratio of -1.45 and a beta of 2.38. Caribou Biosciences has a 12 month low of $1.38 and a 12 month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.28 million.

Hedge Funds Weigh In On Caribou Biosciences

Several large investors have recently modified their holdings of CRBU. Bronte Capital Management Pty Ltd. acquired a new position in shares of Caribou Biosciences in the 4th quarter worth approximately $25,000. Creative Planning bought a new position in shares of Caribou Biosciences in the 2nd quarter worth about $25,000. CTC Alternative Strategies Ltd. bought a new position in shares of Caribou Biosciences in the 1st quarter worth about $29,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $30,000. Finally, Next Capital Management LLC acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at about $35,000. Institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source